Quanterix is a Massachusetts company with an ultra-sensitive, versatile Covid-19 antigen test, and they are also the company behind the digital health solution Simoa. Quanterix is a Massachusetts-based medical company that has developed a laboratory Covid-19 antigen test that uses an ultra-sensitive single-molecule assay to analyze a number of sample types, including nasal swabs, saliva, or finger-prick blood samples. Prior to the outbreak of Covid-19, Quanterix released the digital health solution Simoa, which allows researchers to closely examine critical biomarkers of infectious diseases. The company focuses on early detection, better prognoses, and enhanced treatment methods. Quanterix’s technology has applications in…
Browsing: Diagnostics Tech
Illumina is a San Diego-based company with a unique Next-Generation Sequencing approach that allows for widespread, fast, and accurate Covid-19 testing across the nation. Illumina is a San Diego-based genomics company that has created a “MegaLab” for scaled-up, next-gen Covid-19 testing using genomic sequencing. To date, the company has received over $12 million in funding from the NIH. Originally founded as a startup, Illumina set out to transform human health and explore DNA at an entirely new scale. Prior to the outbreak of Covid-19, Illumina was exploring concepts like the cause of cancer and genetic variations. The company’s key mission…
MIT researchers have found a new angle: applying AI to detect COVID-19 in an asymptomatic patient. From a cough. Recorded by a phone. Earlier this year, researchers from MIT solicited tens of thousands of recorded “forced” (i.e. not naturally occurring) coughs from over 5,300 subjects – both COVID-positive and COVID-negative – in addition to data about physical symptoms and demographics. They then used that data to train a revised version of their Alzheimer’s model (That had been the target of earlier research with this technology) to distinguish between COVID-infected and COVID-uninfected coughers. MIT researchers had been working on AI cough…
Biobot Analytics tracks the spread of Covid-19 by analyzing the wastewater of a given population, and this method is cheaper than individual testing while offering earlier warnings and better trend analysis. Biobot Analytics is a Cambridge-based wastewater analysis company with strong links to MIT. With its patented technology, Biobot takes a unique approach to Covid-19 testing. By analyzing wastewater samples, this company can detect spikes in Covid-19 cases before individuals have displayed any symptoms. This approach is cheaper than individual mass testing, and it also offers earlier warnings and superior trend analysis. Founded by students at MIT, Biobot Analytics was…
Luminostics is a medical diagnostics company that specializes in rapid, accurate self-tests for infectious diseases that can be carried out by consumers at home. The company’s expressed mission is to “increase healthcare accessibility and efficiency by designing, developing, manufacturing, and delivering products that enable affordable, widespread access to actionable health testing with immediate follow-up.” In recent months, Luminostics has become one of the global leaders in innovative Covid-19 testing methods. Their unique approach involves an iOS/Android app that integrated with an inexpensive adapter, using nanochemistry and signal processing artificial intelligence to detect and measure viruses with a high level of…
The Contagion Conference on Testing will look at the critical issues and challenges posed by COVID-19 and will present technologies and approaches that can enable society to open and avert the need for lockdowns. The Virtual event will be broadcast from New York City and will feature panels on The Conference will present the latest research findings on how testing can control the spread. It will present promising technologies seeking strategic partners to accelerate their development. Presenting firms will include those which received NIH Funding as part of the RADx “Shark Tank” competition which has awarded $437 million in contracts to the…
Fluidigm COVID-19 Campus Safeguard Program Improves Availability of Noninvasive, Saliva-Based SARS-CoV-2 Tests for Higher Education Institutions. SOUTH SAN FRANCISCO, Calif., Oct. 08, Fluidigm Corporation (Nasdaq:FLDM), announced a program to expand availability of Fluidigm® COVID-19 tests for U.S. colleges and universities. The Fluidigm COVID-19 Campus Safeguard Program will provide millions of noninvasive, saliva-based tests for the SARS-CoV-2 virus to qualifying institutions at a cost as low as $5 per test. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay on the high-throughput Fluidigm Biomark™ HD system features an integrated testing platform and a reliable supply chain and can be easily combined with commonly available…
The National Institutes of Health (NIH) Biomedical Advanced Research and Development Authority (BARDA), announced a third round of contract awards for scale-up and manufacturing of new COVID-19 testing technologies. The six new Rapid Acceleration of Diagnostics (RADx) initiative contracts total $98.35 million for point-of-care and other novel test approaches that provide new modes of sample collection, processing and return of results. Innovations in these new technologies include integration with smart devices, mobile-lab processing that can be deployed to COVID-19 hot spots, and test results available within minutes. These awards are part of the RADx Tech program, focused on rapidly advancing early testing…